FindTrial
Sign In

The Effect of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) on Overall Survival of Patients with Relapsed Diffuse Large B-Cell Lymphoma Post-Autologous Stem Cell Transplant

The Effect of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) on Overall Survival of Patients with Relapsed Diffuse Large B-Cell Lymphoma Post-Autologous Stem Cell Transplant

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12610000803099
Acronym
The Possible Study
Enrollment
150
Registered
2010-09-27
Start date
2010-11-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Hypothesis: Relapsed diffuse large B-cell lymphoma (DLBCL) patients who received R-CHOP as their primary therapy have a poor outcome compared to patients who received CHOP as their primary therapy. The objective of this study is to assess the impact of R-CHOP on the overall survival of autologous stem cell transplant for patients with relapsed DLBCL. The information gained may benefit patients by altering standard therapy for this patient population.

Interventions

Not applicable - retrospective chart review study. The retrospective chart review will involve the review of 150 - 200 patient charts, dating from 1996 to 2010, to examine the outcomes for patients with relapsed Diffuse Large B-Cell Lymphoma (DLBCL) undergoing auto-Stem Cell Transplant (auto-SCT) at the Haematology & Oncology Clinics of Australia (HOCA). Cohort analysis will be completed on two groups of patients: 1) patients who received CHOP chemotherapy and underwent auto-SCT for relapsed D

Not applicable - retrospective chart review study. The retrospective chart review will involve the review of 150 - 200 patient charts, dating from 1996 to 2010, to examine the outcomes for patients with relapsed Diffuse Large B-Cell Lymphoma (DLBCL) undergoing auto-Stem Cell Transplant (auto-SCT) at the Haematology & Oncology Clinics of Australia (HOCA). Cohort analysis will be completed on two groups of patients: 1) patients who received CHOP chemotherapy and underwent auto-SCT for relapsed DLBCL and 2) patients who received R-CHOP for relapsed DLBCL. Total length of time for study is approximately 12 months with an expected end date of December 2011.

Sponsors

Haematology and Oncology Clinics (HOCA) Research Centre
Lead SponsorCharities/Societies/Foundations

Eligibility

Sex/Gender
All
Age
0 to No maximum
Healthy volunteers
No

Inclusion criteria

Patients with histologically-confirmed DLBCL Must have received CHOP (CHOP 14, CHOP 21) or R-CHOP (R-CHOP 14, R-CHOP 21) chemotherapy as first-line therapy Must have received an auto-SCT transplant after relapse

Exclusion criteria

Patients with low-grade lymphoma at presentation or relapse.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026